Detection of polyunsaturated omega-6 fatty acid in human malignant prostate tissue by 1D and 2D high-resolution magic angle spinning NMR spectroscopy

Stenman, Katarina; Hauksson, Jón; Gröbner, Gerhard; Stattin, Pär; Bergh, Anders; Riklund, Katrine

doi:10.1007/s10334-009-0187-x

Cited by 23 publications

(28 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1B; 100% malignant, Fig. 1C; corresponding morphological pictures are presented on the left side of each NMR spectrum), as indicated, including: lactate (1.33 ppm), alanine (1.48 and 3.78 ppm), glutamate (2.05, 2.15, and 2.35 ppm), glutamine (2.14 and 2.47 ppm), citrate (2.55 and 2.65 ppm), diallylic protons (omega-6,20 2.80 ppm), creatine (3.02 and 3.94 ppm), polyamines (3.05–3.15 ppm), choline (3.20 ppm), glycerophosphorylcholine + phosphorylcholine (GPCho + PCho, 3.22 ppm), taurine (3.25 and 3.46 ppm), myo-inositol (3.29 and 3.52–3.62 ppm) and scyllo-inositol (3.35 ppm).…”

Section: Resultsmentioning

confidence: 99%

H HRMAS NMR Derived Bio-markers Related to Tumor Grade, Tumor Cell Fraction, and Cell Proliferation in Prostate Tissue Samples

Stenman¹,

Stattin

Stenlund

et al. 2011

Biomark�Insights

Self Cite

View full text Add to dashboard Cite

A high-resolution magic angle spinning NMR spectroscopic approach is presented for evaluating the occurrence, amount and aggressiveness of cancer in human prostate tissue samples. Using this technique, key metabolites in malignant and non-malignant samples (n = 149) were identified, and patterns of their relative abundance were analyzed by multivariate statistical methods. Ratios of various metabolites – including (glycerophophorylcholine + phosphorylcholine)/creatine, myo-inositol/scyllo-inositol, scyllo-inositol/creatine, choline/creatine, and citrate/creatine – correlated with: i) for non-malignant tissue samples, the distance to the nearest tumor and its Gleason score and; ii) the fraction of tumor cells present in the sample; and iii) tumor cell proliferation (Ki67 labelling index). This NMR-based approach allows the extraction of information that could be useful for developing novel diagnostic methods for prostate cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

H HRMAS NMR Derived Bio-markers Related to Tumor Grade, Tumor Cell Fraction, and Cell Proliferation in Prostate Tissue Samples

Stenman¹,

Stattin

Stenlund

et al. 2011

Biomark�Insights

Self Cite

View full text Add to dashboard Cite

show abstract

“…Several metabolomics studies performed in PCa tissue revealed an increase of choline levels in PCa samples, which indicates alterations in phospholipid membrane synthesis and hydrolysis (Table 4) [84], [86], [88], [89], [92], [93], [94]. Because this elevated proliferation rate also increases cell energy requirements, PCa samples also have alterations in lipid metabolism (as lipids may be used by the cells to produce energy) (Table 4) [49], [95].…”

Section: Altered Metabolism Of Pca Cellsmentioning

confidence: 99%

Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies

Lima

Bastos

Carvalho

et al. 2016

Translational Oncology

121

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most frequently diagnosed cancer and the second leading cause of cancer death among men in Western countries. Current screening techniques are based on the measurement of serum prostate specific antigen (PSA) levels and digital rectal examination. A decisive diagnosis of PCa is based on prostate biopsies; however, this approach can lead to false-positive and false-negative results. Therefore, it is important to discover new biomarkers for the diagnosis of PCa, preferably noninvasive ones. Metabolomics is an approach that allows the analysis of the entire metabolic profile of a biological system. As neoplastic cells have a unique metabolic phenotype related to cancer development and progression, the identification of dysfunctional metabolic pathways using metabolomics can be used to discover cancer biomarkers and therapeutic targets. In this study, we review several metabolomics studies performed in prostatic fluid, blood plasma/serum, urine, tissues and immortalized cultured cell lines with the objective of discovering alterations in the metabolic phenotype of PCa and thus discovering new biomarkers for the diagnosis of PCa. Encouraging results using metabolomics have been reported for PCa, with sarcosine being one of the most promising biomarkers identified to date. However, the use of sarcosine as a PCa biomarker in the clinic remains a controversial issue within the scientific community. Beyond sarcosine, other metabolites are considered to be biomarkers for PCa, but they still need clinical validation. Despite the lack of metabolomics biomarkers reaching clinical practice, metabolomics proved to be a powerful tool in the discovery of new biomarkers for PCa detection.

show abstract

“…4. Other metabolites that have been reported to be markers for PCa vs. normal and BPH prostate tissues include sarcosine 31 , lactate 21 , taurine 30 , glutamate 30 , lysine 29 , myo-inositol 27 , and omega-6-fatty acids 72 , all of which may be present at significantly higher levels in PCa tissues.…”

Section: Metabolism In Prostate Cancer Cellsmentioning

confidence: 99%

Recent Advances in Metabolic Profiling and Imaging of Prostate Cancer

Thapar¹,

Titus²

2014

CMB

View full text Add to dashboard Cite

Cancer is a metabolic disease. Cancer cells, being highly proliferative, show significant alterations in metabolic pathways such as glycolysis, respiration, the tricarboxylic acid (TCA) cycle, oxidative phosphorylation, lipid metabolism, and amino acid metabolism. Metabolites like peptides, nucleotides, products of glycolysis, the TCA cycle, fatty acids, and steroids can be an important read out of disease when characterized in biological samples such as tissues and body fluids like urine, serum, etc. The cancer metabolome has been studied since the 1960s by analytical techniques such as mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy. Current research is focused on the identification and validation of biomarkers in the cancer metabolome that can stratify high-risk patients and distinguish between benign and advanced metastatic forms of the disease. In this review, we discuss the current state of prostate cancer metabolomics, the biomarkers that show promise in distinguishing indolent from aggressive forms of the disease, the strengths and limitations of the analytical techniques being employed, and future applications of metabolomics in diagnostic imaging and personalized medicine of prostate cancer.

show abstract

Detection of polyunsaturated omega-6 fatty acid in human malignant prostate tissue by 1D and 2D high-resolution magic angle spinning NMR spectroscopy

Abstract: It is possible to detect PUFAs in prostate tissues using our NMR-based spectroscopic approach.

Cited by 23 publications

References 15 publications

H HRMAS NMR Derived Bio-markers Related to Tumor Grade, Tumor Cell Fraction, and Cell Proliferation in Prostate Tissue Samples

H HRMAS NMR Derived Bio-markers Related to Tumor Grade, Tumor Cell Fraction, and Cell Proliferation in Prostate Tissue Samples

Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies

Recent Advances in Metabolic Profiling and Imaging of Prostate Cancer

Contact Info

Product

Resources

About